<DOC>
	<DOC>NCT02021643</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of sofosbuvir+ribavirin (RBV), +/- pegylated interferon, in treatment-naive and treatment-experienced adults with chronic genotype 1, 2, 3 or 6 HCV infection. The study will be conducted in China, Hong Kong (HK), Korea, Taiwan, and Vietnam. Participants will be enrolled in the study for 12, 16, or 24 weeks of treatment.</brief_summary>
	<brief_title>Efficacy and Safety of Sofosbuvir Plus Ribavirin in Subjects With Chronic HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key Willing and able to provide written informed consent HCV RNA â‰¥ 10^4 IU/mL at screening HCV treatmentnaive (HCV genotype 1, 2, 3 or 6), defined as no prior exposure to any interferon (IFN), RBV, or other approved or experimental HCVspecific directacting antiviral agent, or HCV treatmentexperienced (HCV genotype 1, 2, 3, or 6 only) with medical records that include sufficient detail of prior treatment with IFN to allow for categorization of prior response as either IFN Intolerant, nonresponder, or experiences viral breakthrough or relapse HCV infection documented by antiHCV antibody test, genotyping test, or liver biopsy Key Current or prior history of any clinicallysignificant illness (other than HCV) Pregnant or nursing female or male with pregnant female partner Chronic liver disease of a nonHCV etiology Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>